{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:52Z","timestamp":1786988152215,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014028","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["674909"],"award-info":[{"award-number":["674909"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejps.2021.106034","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T01:24:48Z","timestamp":1633742688000},"page":"106034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state"],"prefix":"10.1016","volume":"168","author":[{"given":"Patrick J","family":"O'Dwyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J","family":"Box","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Imanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vertzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Reppas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.106034_bib0001","unstructured":"AbbVie Deutschland GmbH & Co. KG., 2016. Norvir 100 mg tablets. Summary of Product Characteristics."},{"key":"10.1016\/j.ejps.2021.106034_bib0002","unstructured":"Accord-UK Ltd, 2018. Diclofenac Potassium 50 mg Tablets. Summary of Product Characteristics."},{"key":"10.1016\/j.ejps.2021.106034_bib0003","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejps.2017.03.011","article-title":"European Journal of Pharmaceutical Sciences Mechanistic investigation of the negative food effect of modified release zolpidem","volume":"102","author":"Andreas","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0004","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1365-2036.2009.03947.x","article-title":"Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging","volume":"29","author":"Babaei","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2021.106034_bib0005","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1208\/s12248-017-0085-5","article-title":"Evolution of choice of solubility and dissolution media after two decades of biopharmaceutical classification system","volume":"19","author":"Bou-Chacra","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2021.106034_bib0006","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0007","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2017.04.029","article-title":"Gastrointestinal behavior of itraconazole in humans \u2013 Part 1: supersaturation from a solid dispersion and a cyclodextrin-based solution","volume":"525","author":"Brouwers","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0008","series-title":"Chapter 31 - Process Development and Scale-Up: Twin-Screw Extrusion","first-page":"821","article-title":"Developing solid oral dosage forms (second edition)","author":"Chen","year":"2017"},{"key":"10.1016\/j.ejps.2021.106034_bib0009","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/jps.21525","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium","volume":"98","author":"Chuasuwan","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00003088-199733030-00003","article-title":"Clinical pharmacokinetics of diclofenac therapeutic insights and pitfalls","volume":"33","author":"Davies","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.106034_bib0011","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3390\/pharmaceutics12070670","article-title":"Exploring the effect of esomeprazole on gastric and duodenal fluid volumes and absorption of ritonavir","volume":"12","author":"de Waal","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106034_bib0012","first-page":"489","article-title":"Metabolism and disposition of the HIV-1 Protease Inhibitor Ritonavir (ABT-538) in Rats, Dogs, and Humans","volume":"25","author":"Denissen","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2021.106034_bib0013","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s11095-013-0974-y","article-title":"Design of biorelevant test setups for the prediction of diclofenac in vivo features after oral administration","volume":"30","author":"Guhmann","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.106034_bib0014","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/0044011-200828120-00005","article-title":"Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Gursoy","year":"2008","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejps.2021.106034_bib0015","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0016","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1208\/s12248-018-0217-6","article-title":"Measuring the impact of gastrointestinal variables on the systemic outcome of two suspensions of posaconazole by a PBPK Model","volume":"20","author":"Hens","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2021.106034_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2125.2005.02226.x","article-title":"Bioavailability of diclofenac potassium at low doses","volume":"59","author":"Hinz","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106034_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir: clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2021.106034_bib0019","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpb.2020.08.005","article-title":"Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: orBiTo consortium commentary","volume":"155","author":"Jamei","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2021.106034_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105001","article-title":"Biphasic drug release testing coupled with diffusing wave spectroscopy for mechanistic understanding of solid dispersion performance","volume":"137","author":"Jankovic","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0022","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1208\/s12249-008-9161-6","article-title":"A standardized mini paddle apparatus as an alternative to the standard paddle","volume":"9","author":"Klein","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2021.106034_bib0023","first-page":"552","article-title":"Indinavir and ritonavir by human intestinal microsomes and expressed cytochrome p450 3A4\/3A5\u00a0: mechanism-based inactivation of cytochrome p4503A by ritonavir","volume":"26","author":"Koudriakova","year":"1998","journal-title":"DRUG Metab. Dispos."},{"key":"10.1016\/j.ejps.2021.106034_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1208\/s12248-018-0231-8","article-title":"The BioGIT System: a valuable in vitro tool to assess the impact of dose and formulation on early exposure to low solubility drugs after oral administration","volume":"20","author":"Kourentas","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2021.106034_bib0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.11.012","article-title":"An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: design, implementation, and evaluation","volume":"82","author":"Kourentas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105031","article-title":"Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states","volume":"138","author":"Litou","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0027","article-title":"Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state","volume":"105297","author":"Litou","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0028","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s11095-016-1882-8","article-title":"Characteristics of the human upper gastrointestinal contents in the fasted state under hypo- and a-chlorhydric gastric conditions under conditions of typical drug \u2013 drug interaction studies","volume":"33","author":"Litou","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.106034_bib0029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejpb.2017.02.009","article-title":"The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen\u00a0: data in biorelevant media and in human aspirates","volume":"115","author":"Litou","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2015.03.009","article-title":"In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: choosing the appropriate test media","volume":"93","author":"Markopoulos","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0031","first-page":"43","article-title":"Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations","volume":"50","author":"Marzo","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2021.106034_bib0032","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1021\/mp1001203","article-title":"Dynamic dissolution: a step closer to predictive dissolution testing?","volume":"7","author":"McAllister","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0033","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/jphp.12478","article-title":"Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir","volume":"68","author":"Miller","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106034_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jphp.12151","article-title":"Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir\/ritonavir in healthy volunteers","volume":"66","author":"Morcos","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106034_bib0035","doi-asserted-by":"crossref","first-page":"P247","DOI":"10.1186\/1758-2652-11-S1-P247","article-title":"The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects","volume":"11","author":"Ng","year":"2008","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ejps.2021.106034_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030272","article-title":"On the usefulness of two small-scale in vitro setups in the evaluation of luminal precipitation of lipophilic weak bases in early formulation development","volume":"12","author":"O\u2019Dwyer","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106034_bib0037","doi-asserted-by":"crossref","DOI":"10.1111\/jphp.12951","article-title":"In vitro methods to assess drug precipitation in the fasted small intestine \u2013 a PEARRL review","volume":"71","author":"O'Dwyer","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106034_bib0038","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1021\/acs.molpharmaceut.7b00406","article-title":"Model-based analysis of biopharmaceutic experiments to improve mechanistic oral absorption modeling: an integrated in vitro in vivo extrapolation perspective using Ketoconazole as a model drug","volume":"14","author":"Pathak","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0039","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.xphs.2018.11.034","article-title":"Biopharmaceutic IVIVE mechanistic modeling of single- and two-phase in vitro experiments to obtain drug-specific parameters for incorporation into PBPK Models","volume":"108","author":"Pathak","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0040","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods","volume":"98","author":"Poulin","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0041","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.106034_bib0042","unstructured":"Rowland, M., Tozer, T.N., 1995. Clinical pharmacokinetics: concepts and applications, 3rd ed."},{"key":"10.1016\/j.ejps.2021.106034_bib0043","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijpharm.2018.07.017","article-title":"Exploring gastric drug absorption in fasted and fed state rats","volume":"548","author":"Rubbens","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105750","article-title":"Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - case example dipyridamole","volume":"160","author":"Segregur","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0045","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1016\/j.xphs.2019.06.021","article-title":"Impact of acid-reducing agents on gastrointestinal physiology and design of biorelevant dissolution tests to reflect these changes","volume":"108","author":"Segregur","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0046","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0022-3565(24)35211-5","article-title":"Interaction of diclofenac and quinidine in monkeys\u00a0: stimulation of diclofenac metabolism","volume":"291","author":"Tang","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2021.106034_bib0047","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jps.24647","article-title":"Gastrointestinal behavior of weakly acidic BCS class II drugs in man - case study of diclofenac potassium","volume":"105","author":"Van Den Abeele","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105377","article-title":"The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation","volume":"151","author":"Van Den Abeele","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106034_bib0049","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1021\/acs.molpharmaceut.7b00253","article-title":"Gastrointestinal and systemic disposition of diclofenac under fasted and fed state conditions supporting the evaluation of in vitro predictive tools","volume":"14","author":"Van Den Abeele","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.106034_bib0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2125.1989.tb03515.x","article-title":"Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: application to diclofenac","volume":"28","author":"Vidon","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106034_bib0051","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00568201","article-title":"The pharmacokinetics of diclofenac sodium following intravenous and oral administration","volume":"16","author":"Willis","year":"1979","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106034_bib0052","unstructured":"Wisdom Pharmaceutical Technology Co Limited, 2020. Voltfast sachets 50 mg powder for oral solution summary of product characteristics."},{"key":"10.1016\/j.ejps.2021.106034_bib0053","doi-asserted-by":"crossref","unstructured":"Xu, H., Vela, S., Shi, Y., Marroum, P., Gao, P., 2017. In Vitro characterization of ritonavir drug products and correlation to human in vivo performance. Mol. Pharm. 14, 3801\u20133814. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00552.","DOI":"10.1021\/acs.molpharmaceut.7b00552"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:59:29Z","timestamp":1760529569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721003377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":53,"alternative-id":["S0928098721003377"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106034","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106034"}}